Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 in Treatment-naïve Severe Aplastic Anemia
NCT07345000Phase 3Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Oct 2029
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of romiplostim in aplastic anemia, sponsored by Qilu Pharmaceutical. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT07345000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07345000.